Du är här


Swedish Orphan Biovitrum AB (publ): Bo Jesper Hansen to step down as Chairman of Sobi - Håkan Björklund to be nominated as new Chairman of the Board

Swedish Orphan Biovitrum AB's (publ)(Sobi(TM)) Chairman of the Board, Bo
Jesper Hansen, MD, PhD, has informed the Sobi's nomination committee that he
will not stand for re-election at the 2016 annual general meeting of
shareholders (AGM). Bo Jesper Hansen has been Chairman of the Board since the
merger of Biovitrum and Swedish Orphan International in 2010. During his
tenure, Sobi has grown to become an international pioneer in rare diseases
with a strong commercial footprint across Europe, North America, the Middle
East and Russia.

The Nomination Committee will propose that the shareholders elect Håkan
Björklund, PhD, as the new Chairman of the Board for Sobi. Håkan Björklund is
the former CEO of Nycomed and currently serves as Industry Executive at
Avista Capital Partners. He has served as a Member of the Board of Directors
of several international life science companies including Alere, Coloplast,
Danisco, and Lundbeck. Between 2001 and 2007, Håkan Björklund also served as
member of the Board of Directors for Biovitrum.

The nomination committee's work will continue and the rest of the committee's
proposals will be announced at a later date in connection with the notice of
the 2016 Annual General Meeting.


About Sobi(TM)

Sobi is an international speciality healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primary
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products for partner companies
across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed
on NASDAQ OMX Stockholm. More information is available atwww.sobi.com.

For more information please contact

| Media relations Investor relations |
| Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
|+46 70 410 71 80 +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| oskar.bosson@sobi.com jorgen.winroth@sobi.com |
| |
The information set out in this press release is announced in accordance with
the Swedish Securities Market Act. The information was submitted for
publication on 26 February 2016 at 08:00 CET.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.